The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia

Leukemia Research

Volumn 31, Issue 7, 2007, Pages 947-953

  Barragan, Eva ^a   Collado, Maria ^a   Cervera, Jose ^b   Martin, Guillermo ^b   Bolufer, Pascual ^a   Roman, Jose ^c   Sanz, Miguel A ^b  

^a Molecular Biology Laboratory (Dpt Medical Pathology)   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Acute myeloid leukemia; Metabolizing enzymes; Polymorphism; Prognosis

Indexed keywords

ANTHRACYCLINE; CYTARABINE; CYTOCHROME P450 1A1; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; ETOPOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHROMOSOME ANALYSIS; DISEASE FREE SURVIVAL; DNA POLYMORPHISM; FEMALE; GENE DELETION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT OUTCOME;

ACUTE DISEASE; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE-FREE SURVIVAL; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE DELETION; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, GENETIC; SURVIVAL RATE;

EID: 34249790283     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.10.002     Document Type: Article

References (31)

1. Appelbaum F.R., and Kopecky K.J. Long-term survival after chemotherapy for acute myeloid leukemia: the experience of the Southwest Oncology Group. Cancer 80 (1997) 2199-2204
2. Bloomfield C.D., Shuma C., Regal L., Philip P.P., Hossfeld D.K., Hagemeijer A.M., et al. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer 80 (1997) 2191-2198
3. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., et al. The importance of diagnostic cytogenetics on outcome AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood 92 (1998) 2322-2323
4. Tsuchida S., and Sato K. Glutathione transferases and cancer. Crit Rev Biochem Mol Biol 27 (1992) 337-384
5. Weinshilboum R. Inheritance and drug response. N Engl J Med 348 (2003) 529-537
6. Friche E., Danks M.K., and Beck W.T. Characterization of tumor cell resistance to 4′-deoxy-4′-iododoxorubicin developed in Ehrlich ascites cells in vivo. Cancer Res 52 (1992) 5701-5706
7. Ingelman-Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res 482 (2001) 11-19
8. Traver R.D., Horikoshi T., Danenberg K.D., Stadlbauer T.H., Danenberg P.V., Ross D., et al. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 52 (1992) 797-802
9. Voso M.T., D'Alo F., Putzulu R., Mele L., Scardocci A., Chiusolo P., et al. Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood 100 (2002) 2703-2707
10. Davies S.M., Robison L.L., Buckley J.D., Tjoa T., Woods W.G., Radloff G.A., et al. Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J Clin Oncol 19 (2001) 279-287
11. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Br J Haematol 33 (1976) 451-458
12. In: Mitelman F. (Ed). ISCN 1995: an international system for human cytogenetic nomenclature 1995 (1995), S Karger, Basel, Switzerland
13. Nakao M., Yokota S., Iwai T., Kaneko H., Horiike S., Kashima K., et al. Internal tandem duplications of the FLT3 gene found in acute myeloid leukemia. Leukemia 10 (1996) 1911-1918
14. Moreno I., Martin G., Bolufer P., Barragan E., Rueda E., Roman J., et al. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica 88 (2003) 19-24
15. Harth V., Bruning T., Abel J., Koch B., Berg I., Sachinidis A., et al. Real-time genotyping of cytochrome P4501A1 A4889G and T6235C polymorphisms. Mol Cell Probes 15 (2001) 93-97
16. Von Ahsen N., Richter M., Grupp C., Ring B., Oellerich M., and Armstrong V.W. No influence of the MDR-I C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 47 (2001) 1048-1052
17. Choi J.Y., Abel J., Neuhaus T., Ko Y., Harth V., Hamajima N., et al. Role of alcohol and genetic polymorphisms of CYP2E1 and ALDH2 in breast cancer development. Pharmacogenetics 13 (2003) 67-72
18. Harth V., Donat S., Ko Y., Abel J., Vetter H., and Bruning T. NAD(P)H quinone oxidoreductase 1 codon 609 polymorphism and its association to colorectal cancer. Arch Toxicol 73 (2000) 528-531
19. Naoe T., Takeyama K., Yokozawa T., Kiyoi H., Seto M., Uike N., et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 6 (2000) 4091-4095
20. Kaplan E.L., and Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
21. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50 (1966) 163-170
22. Cox D.R. Regression models and life tables (with discussion). JR Stat Soc B 34 (1972) 187-220
23. Birch J.M. Genes and cancer. Arch Dis Child 80 (1999) 1-3
24. Pan S., Forrest G., Akman S., and Hu L. NAD(P)H:quinone oxidoreductase expression and mitomycin C resistance developed by human colon cancer HCT 116 cells. Cancer Res 55 (1995) 330-335
25. Powis G. Free radical formation by antitumor quinines. Free Radic Biol Med 6 (1989) 63-101
26. Gutierrez P.L. The role of NAD(P)H oxidoreductase (DT-diaphorase) in the bioactivation of quinone-containing antitumor agents: a review. Free Radic Biol Med 29 (2000) 263-275
27. Krajinovic M., Labuda D., Mathonnet G., Labuda M., Moghrabi A., Champagne J., et al. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res 8 (2002) 802-810
28. Naoe T., Tagawa Y., Kiyoi H., Kodera Y., Miyawaki S., Asou N., et al. Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy. Leukemia 16 (2002) 203-208
29. Rocha J.C., Cheng C., Liu W., Kishi S., Das S., Cook E.H., et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105 (2005) 4752-4758
30. Sanchez R.I., Mesia-Vela S., and Kauffman F.C. Induction of NAD(P)H quinone oxidoreductase and glutathione S-transferase activities in livers of female August-Copenhagen Irish rats treated chronically with estradiol: comparison with the Sprague-Dawley rat. J Steroid Biochem Mol Biol 87 (2003) 199-206
31. Voso M.T., D'Alo F., Gumiero D., Guidi F., Hohaus S., and Leone G. The CYP1A1*2A allele is an independent prognostic factor for acute myeloid leukemia. Haematologica 90 (2005) 982-984